Logo image of ANIK

ANIKA THERAPEUTICS INC (ANIK) Stock Fundamental Analysis

NASDAQ:ANIK - Nasdaq - US0352551081 - Common Stock - Currency: USD

10.83  -0.29 (-2.61%)

After market: 10.83 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ANIK. ANIK was compared to 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANIK as it has an excellent financial health rating, but there are worries on the profitability. ANIK is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ANIK has reported negative net income.
In the past year ANIK had a positive cash flow from operations.
ANIK had negative earnings in 4 of the past 5 years.
Of the past 5 years ANIK 4 years had a positive operating cash flow.
ANIK Yearly Net Income VS EBIT VS OCF VS FCFANIK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

The Return On Assets of ANIK (-29.77%) is better than 67.03% of its industry peers.
The Return On Equity of ANIK (-38.24%) is better than 71.51% of its industry peers.
Industry RankSector Rank
ROA -29.77%
ROE -38.24%
ROIC N/A
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ANIK Yearly ROA, ROE, ROICANIK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

Looking at the Gross Margin, with a value of 60.61%, ANIK is in the better half of the industry, outperforming 78.85% of the companies in the same industry.
In the last couple of years the Gross Margin of ANIK has declined.
The Profit Margin and Operating Margin are not available for ANIK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
ANIK Yearly Profit, Operating, Gross MarginsANIK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

ANIK does not have a ROIC to compare to the WACC, probably because it is not profitable.
ANIK has less shares outstanding than it did 1 year ago.
ANIK has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANIK Yearly Shares OutstandingANIK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANIK Yearly Total Debt VS Total AssetsANIK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 3.90 indicates that ANIK is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.90, ANIK is doing good in the industry, outperforming 75.27% of the companies in the same industry.
There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.9
ROIC/WACCN/A
WACC8.93%
ANIK Yearly LT Debt VS Equity VS FCFANIK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 5.73 indicates that ANIK has no problem at all paying its short term obligations.
ANIK has a Current ratio of 5.73. This is comparable to the rest of the industry: ANIK outperforms 59.32% of its industry peers.
ANIK has a Quick Ratio of 4.53. This indicates that ANIK is financially healthy and has no problem in meeting its short term obligations.
ANIK has a Quick ratio of 4.53. This is comparable to the rest of the industry: ANIK outperforms 50.54% of its industry peers.
Industry RankSector Rank
Current Ratio 5.73
Quick Ratio 4.53
ANIK Yearly Current Assets VS Current LiabilitesANIK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

ANIK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.00%, which is quite impressive.
The Revenue for ANIK has decreased by -18.80% in the past year. This is quite bad
The Revenue has been growing slightly by 0.91% on average over the past years.
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.68%
Revenue 1Y (TTM)-18.8%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-35.42%

3.2 Future

The Earnings Per Share is expected to grow by 28.24% on average over the next years. This is a very strong growth
Based on estimates for the next years, ANIK will show a quite strong growth in Revenue. The Revenue will grow by 11.88% on average per year.
EPS Next Y45.8%
EPS Next 2Y37.59%
EPS Next 3Y25.78%
EPS Next 5Y28.24%
Revenue Next Year-26.79%
Revenue Next 2Y-10.38%
Revenue Next 3Y-5.57%
Revenue Next 5Y11.88%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ANIK Yearly Revenue VS EstimatesANIK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
ANIK Yearly EPS VS EstimatesANIK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANIK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANIK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANIK Price Earnings VS Forward Price EarningsANIK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ANIK is valued cheaper than 91.58% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 84.87
ANIK Per share dataANIK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

A more expensive valuation may be justified as ANIK's earnings are expected to grow with 25.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.59%
EPS Next 3Y25.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANIK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANIKA THERAPEUTICS INC

NASDAQ:ANIK (6/26/2025, 8:00:00 PM)

After market: 10.83 0 (0%)

10.83

-0.29 (-2.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-06 2025-08-06/amc
Inst Owners90.31%
Inst Owner Change0.95%
Ins Owners3.44%
Ins Owner Change7.47%
Market Cap155.30M
Analysts86.67
Price Target21.76 (100.92%)
Short Float %3%
Short Ratio6.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-265.53%
Min EPS beat(2)-398.5%
Max EPS beat(2)-132.56%
EPS beat(4)0
Avg EPS beat(4)-546.51%
Min EPS beat(4)-1533.99%
Max EPS beat(4)-121.01%
EPS beat(8)1
Avg EPS beat(8)-467.12%
EPS beat(12)3
Avg EPS beat(12)-314.56%
EPS beat(16)6
Avg EPS beat(16)-204.02%
Revenue beat(2)1
Avg Revenue beat(2)-2.57%
Min Revenue beat(2)-8.59%
Max Revenue beat(2)3.46%
Revenue beat(4)1
Avg Revenue beat(4)-4.31%
Min Revenue beat(4)-9.72%
Max Revenue beat(4)3.46%
Revenue beat(8)5
Avg Revenue beat(8)-0.08%
Revenue beat(12)8
Avg Revenue beat(12)0.82%
Revenue beat(16)12
Avg Revenue beat(16)2.74%
PT rev (1m)-7.25%
PT rev (3m)-11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-209.09%
EPS NY rev (1m)-30.95%
EPS NY rev (3m)-450%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.13
P/FCF N/A
P/OCF 28.77
P/B 1.05
P/tB 1.12
EV/EBITDA 84.87
EPS(TTM)-2.1
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)0.38
OCFY3.48%
SpS9.58
BVpS10.35
TBVpS9.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.77%
ROE -38.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.61%
FCFM N/A
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
F-Score6
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 122.22%
Cap/Sales 6.8%
Interest Coverage N/A
Cash Conversion 431.92%
Profit Quality N/A
Current Ratio 5.73
Quick Ratio 4.53
Altman-Z 3.9
F-Score6
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)64.17%
Cap/Depr(5y)48.11%
Cap/Sales(3y)5.41%
Cap/Sales(5y)4.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.68%
EPS Next Y45.8%
EPS Next 2Y37.59%
EPS Next 3Y25.78%
EPS Next 5Y28.24%
Revenue 1Y (TTM)-18.8%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-35.42%
Revenue Next Year-26.79%
Revenue Next 2Y-10.38%
Revenue Next 3Y-5.57%
Revenue Next 5Y11.88%
EBIT growth 1Y53.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100.02%
EBIT Next 3Y35.85%
EBIT Next 5Y36.1%
FCF growth 1Y19.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y102.97%
OCF growth 3Y-13.68%
OCF growth 5Y-31.94%